OurCrowd portfolio company MigVax Ltd., a startup developing an oral subunit vaccine against COVID-19, has announced promising results from preclinical tests that demonstrated the effectiveness of its MigVax-101 booster for previously vaccinated persons.
According to a note distributed by the company, tests carried out on rats demonstrated that the MigVax-101 subunit oral vaccine, when administered in a boost format following an injected S1 protein, elicited higher neutralizing antibody. Additionally, similar to a third booster injection, it is said to have elicited more effective neutralizing antibodies.
MigVax is currently seeking the financing necessary for it to launch Phase 1 & 2 clinical trials, which, if successful, it believes would lead to commercial availability 9-12 months after the trials begin.
The ease of administration as an oral vaccine could offer advantages over injected vaccines.
Prof. Itamar Shalit, MigVax’s Infectious Disease Expert, stated:
“The results of this trial increase our confidence that our MigVax-101 subunit oral vaccine will make a positive contribution to a world coming to grips with the new post-pandemic reality. Fifteen months into the pandemic, we now see that the struggle to keep Covid under control is nearly as challenging as getting it under control to begin with. Oral boosters such as our MigVax-101 will be key enablers that will help health organizations the world over transition from ‘panic mode’ to routine, due to their ability to reduce the cost and expand the reach of ongoing vaccination programs.”
The first investment round in MigVax was led by OurCrowd.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!
